Illinois Dentist Loses Federal License for Controlled Substances
Published Date: 9/19/2025
Notice
Summary
Eric Andersen, a dentist from Illinois, lost his DEA license to handle controlled substances because he no longer has the state permission to do so. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration in 2025. This means he can’t legally prescribe or manage controlled drugs anymore, effective immediately.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Eric Andersen
The Drug Enforcement Administration revoked DEA Certificate of Registration No. FA2687765 issued to Eric Andersen, D.D.S., because his Illinois dental license and controlled-substance authorizations were revoked on November 25, 2024. The DEA issued an Order to Show Cause on March 18, 2025; Andersen did not request a hearing, and the revocation is effective October 20, 2025.
Pending DEA Applications Denied for Andersen
The DEA also denied any pending applications of Eric Andersen, D.D.S., to renew or modify Registration No. FA2687765 and denied any other pending applications for additional registration in Illinois. That denial is part of the Order effective October 20, 2025.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2025-18170, Octamethylcyclotetrasiloxane (D4); Draft Risk Evaluation; Science Advisory Committee on Chemicals (SACC) Peer Review; Notice of SACC Meeting; Availability of Draft Documents and Request for Comment
The EPA is holding two virtual meetings in late 2025 to review the safety of a chemical called D4, which is used in many products. They want experts and the public to check their draft report and share thoughts before final decisions. This could affect companies using D4 and might lead to new rules to keep people and the environment safe.
Next: 2025-18172, Haroon Hameed, M.D.; Decision and Order
Dr. Haroon Hameed from Maryland lost his DEA license because he abused drugs while treating patients and lied on his renewal application. The DEA decided his actions put the public at risk, so they revoked his registration and denied any future applications. This means he can’t legally prescribe controlled substances anymore, effective immediately.